There are currently 124 clinical trials in Mobile, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including MBCCOP - Gulf Coast, University of South Alabama Mitchell Cancer Institute, Mobile Infirmary Medical Center and University of South Alabama. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: AMR Mobile, Mobile, Alabama +1 locations
Conditions: Obesity
Register for Updates
A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825
Recruiting
A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Site 0170-USA Mitchell Cancer Institute, Mobile, Alabama
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Register for Updates
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
NCT05207670
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Infirmary Cancer Care, Mobile, Alabama
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
NCT05611242
Recruiting
The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe stenosis).
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
04/22/2024
Locations: Mobile Infirmary Medical Center, Mobile, Alabama
Conditions: Acute Ischemic Stroke
Register for Updates
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625
Recruiting
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexa... Read More
Gender:
All
Ages:
Between 365 days and 31 years
Trial Updated:
04/20/2024
Locations: USA Health Strada Patient Care Center, Mobile, Alabama
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Strada Patient Care Center, Mobile, Alabama
Conditions: Focal Onset Seizures
Register for Updates
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895
Recruiting
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: University of South Alabama, Mitchell Cancer Institute ( Site 1582), Mobile, Alabama
Conditions: Urinary Bladder Cancer, Muscle-invasive
Register for Updates
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
04/19/2024
Locations: USA Health Strada Patient Care Center, Mobile, Alabama
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma
NCT04224493
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Southern Cancer Center, Mobile, Alabama
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132
Recruiting
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer come... Read More
Gender:
All
Ages:
50 years and below
Trial Updated:
04/18/2024
Locations: USA Health Strada Patient Care Center, Mobile, Alabama
Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma
Register for Updates
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398
Recruiting
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors wil... Read More
Gender:
All
Ages:
25 years and below
Trial Updated:
04/18/2024
Locations: USA Health Strada Patient Care Center, Mobile, Alabama
Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Register for Updates
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842
Recruiting
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/18/2024
Locations: Research Site, Mobile, Alabama
Conditions: Hepatocellular Carcinoma
Register for Updates